Pancreatic cancer is a highly lethal disease that is very difficult to diagnose. The high mortality of this disease is predominantly due to the advanced stage of disease at the time of diagnosis and a lack of effective treatments. Due to the low prevalence of pancreatic cancer (0.01%), early detection would be most cost-effective in screening increased-risk populations, such as new-onset type-2 diabetics. Clinical and research studies have substantiated the link between pancreatic cancer and new-onset type-2 diabetes. Development of a highly accurate blood-based test to detect pancreatic cancer in this population would represent a breakthrough in early detection of pancreatic cancer. Such a blood test, if used on an annual basis in this higher-risk population, could serve as an effective and inexpensive method for initial targeted screening. In this project, we proposed to develop and characterize a blood-based proteomics signature that allows early detection of pancreatic cancer patients with new-onset diabetics.
The Specific Aims are as follows:
Specific Aim 1 : unbiased global discovery of differential proteins associated with pancreatic cancer in the blood of diabetic patients using quantitative proteomics;
Specific Aim 2 : development of targeted proteomics assay for 35 selected biomarker candidates;
Specific Aim 3 : establishment of a proteomics signature (biomarker panel) for detecting early stage pancreatic cancer in diabetic patients;
Specific Aim 4 : evaluation of the proteomics signature in detecting pancreatic cancer in asymptomatic patients. This proposal builds on our decade-long systematic study of pancreatic tumorigenesis, the rich resource of previous discoveries in pancreatic cancer biomarker development, well-characterized study cohorts from different institutions, as well as cutting-edge proteomics platform technologies that we have developed and implemented. Successful development of a blood-based assay to facilitate the early detection of pancreatic cancer for diabetic patients would alleviate the current prolonged work-up of higher-risk populations and provide critically important interception opportunities to treat earlier stage cancer.
We propose to apply cutting-edge targeted proteomics technologies to develop a blood-based test for early detection of pancreatic cancer in diabetic patients. Successful development of such a blood test, if used on an annual basis in this higher-risk population, could serve as an effective method for initial targeted screening, providing critically important intervention opportunities to treat earlier stage cancer.
|Nigjeh, Eslam N; Chen, Ru; Allen-Tamura, Yasuko et al. (2017) Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer. Proteomics Clin Appl 11:|
|Chen, Ru; Lai, Lisa A; Sullivan, Yumi et al. (2017) Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Sci Rep 7:7950|
|Nigjeh, Eslam N; Chen, Ru; Brand, Randall E et al. (2017) Quantitative Proteomics Based on Optimized Data-Independent Acquisition in Plasma Analysis. J Proteome Res 16:665-676|
|Pan, Sheng; Brentnall, Teresa A; Chen, Ru (2016) Glycoproteins and glycoproteomics in pancreatic cancer. World J Gastroenterol 22:9288-9299|
|Pan, Sheng; Brentnall, Teresa A; Chen, Ru (2015) Proteomics analysis of bodily fluids in pancreatic cancer. Proteomics 15:2705-15|
|Chen, Ru; Dawson, David W; Pan, Sheng et al. (2015) Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Lab Invest 95:43-55|